Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone

Leukemia

Volumn 30, Issue 4, 2016, Pages 776-781

  Kiladjian, J J ^a,b   Giraudier, S ^b,c,d   Cassinat, B ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b Hôpital Saint Louis   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d FACULTÉ DE MÉDECINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CALRETICULIN; HYDROXYUREA; PEGINTERFERON ALPHA; ANTIVIRUS AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; DISEASE ERADICATION; DRUG EFFICACY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; JAK2V617F GENE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TET2 GENE; TREATMENT RESPONSE; MYELOPROLIFERATIVE DISORDERS;

ANTIVIRAL AGENTS; HUMANS; INTERFERON-ALPHA; MYELOPROLIFERATIVE DISORDERS;

EID: 84950265887     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.326     Document Type: Review

References (75)

1. Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 1988; 2: 960-961
2. Ludwig H, Cortelezzi A, Van Camp BG, Polli E, Scheithauer W, Kuzmits R, et al. Treatment with recombinant interferon-Alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases. Oncology 1985; 42: 19-25
3. Silver RT. Recombinant interferon-Alpha for treatment of polycythaemia vera. Lancet 1988; 2: 403
4. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-Alpha therapy in bcr-Abl-negative myeloproliferative neoplasms. Leukemia 2008; 22: 1990-1998
5. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011; 117: 4706-4715
6. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how?. Blood 2014; 124: 3529-3537
7. Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Interferon-Alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 2011; 12: 392-419
8. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-Alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072
9. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418-5424
10. Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol 2014; 90: 288-294
11. Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res 2013; 37: 1041-1045
12. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-770
13. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013; 6: 49-58
14. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-249
15. Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC. Antiproliferative properties of type I and type II interferon. Pharmaceuticals (Basel) 2010; 3: 994-1015
16. Biron CA. Interferons alpha and beta as immune regulators-A new look. Immunity 2001; 14: 661-664
17. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28: 1429-1435
18. Burchert A, Saussele S, Eigendorff E, Müller MC, Sohlbach K, Inselmann S, et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia 2015; 29: 1331-1335
19. Garicochea B, van Rhee F, Spencer A, Chase A, Lin F, Cross NC, et al. Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-Type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). Br J Haematol 1994; 88: 400-402
20. Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol 2012; 159: 172-181
21. Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?. . Leuk Res 2013; 37: 214-220
22. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798
23. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 2015; 372: 426-435
24. Hasselbalch HC. Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol 2014; 7: 203-216
25. Kiladjian JJ, Massé A, Cassinat B, Mokrani H, Teyssandier I, le Couédic JP, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 2010; 24: 1519-1523
26. Hino M, Futami E, Okuno S, Miki T, Nishizawa Y, Morii H. Possible selective effects of interferon alpha-2b on a malignant clone in a case of polycythemia vera. Ann Hematol 1993; 66: 161-162
27. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003; 101: 3294-3301
28. Massaro P, Foa P, Pomati M, LaTargia ML, Iurlo A, Clerici C, et al. Polycythemia vera treated with recombinant interferon-Alpha 2a: evidence of a selective effect on the malignant clone. Am J Hematol 1997; 56: 126-128
29. Messora C, Bensi L, Vecchi A, Longo R, Giacobbi F, Temperani P, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-Alpha. Br J Haematol 1994; 86: 402-404
30. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011; 29: 3907-3913
31. Alvarez-Larrán A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 2012; 119: 1363-1369
32. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45
33. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121: 1720-1728
34. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 2015; 126: 1762-1769
35. Ishii T, Xu M, Zhao Y, Hu WY, Ciurea S, Bruno E, et al. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-Alpha 2a in a patient with polycythemia vera. Leukemia 2007; 21: 373-374
36. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617Fassociated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN & MPNr-EuroNet (COST action BM0902) study. Leukemia 2013; 27: 2032-2039
37. Guglielmelli P, Rotunno G, Bogani C, Mannarelli C, Giunti L, Provenzano A, et al. Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis. Br J Haematol 2015; e-pub ahead of print 25 August 2015; doi: 10.1111/bjh.13644
38. Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon alpha therapy in essential thrombocythemia patients with CALR mutations. Blood 2015; e-pub ahead of print 20 October 2015
39. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project. Blood 2013; 121: 4778-4781
40. Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, et al. Telomerase inhibitor Imetelstat in patients with essential thrombocythemia. N Engl J Med 2015; 373: 920-928
41. Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, et al. A pilot study of the telomerase inhibitor Imetelstat for myelofibrosis. N Engl J Med 2015; 373: 908-919
42. Quintαs-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 2013; 122: 893-901
43. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011; 117: 6669-6672
44. Utke Rank C, Weis Bjerrum O, Larsen TS, Kjær L, de Stricker K, Riley CH, et al. Minimal residual disease after long-Term interferon-Alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma 2015, 1-7
45. Pizzi M, Silver RT, Barel A, Orazi A. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol 2015; 28: 1315-1323
46. Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, et al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013; 162: 783-791
47. Nguyen HM, Kiladjian JJ. Is there a role for the use of IFN-α in primary myelofibrosis?. Hematology Am Soc Hematol Educ Program 2012; 2012: 567-570
48. Larsen TS, Møller MB, de Stricker K, Nørgaard P, Samuelsson J, Marcher C, et al. Minimal residual disease and normalization of the bone marrow after long-Term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009; 14: 331-334
49. Turlure P, Cambier N, Roussel M, Bellucci S, Zini J-M, Rain J-D, et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon {alpha}-2a (peg-IFN{alpha}-2a) therapy in polycythemia vera (PV): long term results of a phase 2 trial. ASH Annual Meeting Abstracts 2011; 118: 280
50. Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep 2014; 9: 331-339
51. Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol 2012; 96: 1-9
52. Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphianegative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood 2011; 118: 2170-2173
53. Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, et al. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α. Eur J Haematol 2015; 94: 227-234
54. Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, et al. Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets and dendritic cells in patients with JAK2(V617F)-positive essential thrombocythemia and polycythemia vera. Eur J Haematol 2015; e-pub ahead of print 19 september 2015; doi: 10.1111/ejh.12687
55. Chaligné R, James C, Tonetti C, Besancenot R, Le Couédic JP, Fava F, et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007; 110: 3735-3743
56. Delhommeau F, Dupont S, Tonetti C, Massé A, Godin I, Le Couedic JP, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007; 109: 71-77
57. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B-And T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007; 136: 745-751
58. James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 2008; 112: 2429-2438
59. Pardanani A, Lasho TL, Finke C, Mesa RA, Hogan WJ, Ketterling RP, et al. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes. Stem Cells 2007; 25: 2358-2362
60. Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A. Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia 2007; 21: 2206-2207
61. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133-1142
62. Gaikwad A, Nussenzveig R, Liu E, Gottshalk S, Chang K, Prchal JT. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol 2007; 35: 587-595
63. Bacher N, Graulich E, Jonuleit H, Grabbe S, Steinbrink K. Interferon-α abrogates tolerance induction by human tolerogenic dendritic cells. PLoS One 2011; 6: e22763
64. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One 2011; 6: e23022
65. Briard D, Brouty-Boyé D, Giron-Michel J, Azzarone B, Jasmin C, Le Bousse-Kerdilès C. Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. Clin Immunol 2003; 106: 201-212
66. Gersuk GM, Carmel R, Pattamakom S, Challita PM, Rabinowitz AP, Pattengale PK. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity. Nat Immun 1993; 12: 136-151
67. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458: 904-908
68. Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies M, et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med 2014; 211: 245-262
69. Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood 2013; 122: 1464-1477
70. Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood 2013; 121: 3692-3702
71. Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-Term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F polycythemia vera. Blood 2012; 120: 166-172
72. Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, et al. Interferon-Alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 2010; 38: 472-480
73. Hasan S, Cassinat B, Droin N, Le Couedic JP, Favale F, Monte-Mor B, et al. Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment. Leukemia 2014; 28: 460-463
74. McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäkel N, Gopalakrishna P, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol 2015; 4: 26
75. Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC. Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-Allele burden in polycythemia vera. Leuk Res Rep 2014; 3: 73-75